{
    "clinical_study": {
        "@rank": "62218", 
        "arm_group": [
            {
                "arm_group_label": "CJ-12420 200 mg + Clarithromycin 500mg", 
                "arm_group_type": "Experimental", 
                "description": "CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days"
            }, 
            {
                "arm_group_label": "CJ-12420 200mg", 
                "arm_group_type": "Active Comparator", 
                "description": "CJ-12420 200mg QD for 5 days"
            }, 
            {
                "arm_group_label": "Clarithromycin 500mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Clarithromycin 500mg BID for 5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective: To assess the effect of the coadministration of multiple dose of CJ-12420\n      and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.\n\n      Secondary Objective(s): To assess the safety of the coadministration of multiple dose of\n      CJ-12420 and clarithromycin in healthy subjects"
        }, 
        "brief_title": "Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "An open-label, randomized, 6-sequence, 3-period, 3-treatment crossover design"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers in the age between 19 and 45 years old\n\n          -  Body mass index(BMI) in the range of 19 to 28 kg/m2\n\n          -  Understand the requirement of the study and voluntarily consent to paticipate in the\n             study\n\n        Exclusion Criteria:\n\n          -  History of clinically significant medical history or disease (hepatic, kidney,\n             gastrointestinal,respiratory, musculoskeletal, endocrine,neuro-psychiatric,\n             haemato-oncologic,urinary tract, cardiac arrhythmia and cardiovascular system) judged\n             by investigator.\n\n          -  Clinically significant abnormal laboratory results within at least 28 days prior to\n             the first day of drug administration. AST or ALT > 1.25 times of upper limit value\n             Total bilirubin > 1.5 times of upper limit value estimated GFR :less than 80 mL/min\n\n          -  Clinically significant abnormal ECG results within at least 28 days prior to the\n             first day of drug administration PR \u2265 210 msec QRS \u2265 120 msec QT \u2265 500 msec QTcF \u2265\n             500 msec\n\n          -  Clinically significant hypersensitivity reaction against investigational drug or\n             other drugs\n\n          -  history of drug abuse or \"positive\" results from drug screening test.\n\n          -  Take medicine such as prescription medicine or herbal medicine, over-the-counter\n             drug, vitamin supplements\n\n          -  Person who have intake history of food or drug which can affect drug absorption, drug\n             distribution, drug metabolism, and drug excretion and bowel activity\n\n          -  Volunteer have a history of donation of whole blood donation, apheresis, transfusion\n\n          -  Volunteer a heavy drinker(30g/day), smoker(10 cigarettes/day), heavy caffeine\n             consumer(400mg/day)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052336", 
            "org_study_id": "CJ_APA_103"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CJ-12420 200mg", 
                    "Clarithromycin 500mg"
                ], 
                "description": "To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.", 
                "intervention_name": "CJ-12420 200mg + Clarithromycin 500mg", 
                "intervention_type": "Drug", 
                "other_name": "CJ-12420 200mg for 5 days + Clarithromycin 500mg for 5 days"
            }, 
            {
                "arm_group_label": [
                    "CJ-12420 200 mg + Clarithromycin 500mg", 
                    "Clarithromycin 500mg"
                ], 
                "description": "To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.", 
                "intervention_name": "CJ-12420 200mg", 
                "intervention_type": "Drug", 
                "other_name": "CJ-12420 200mg for 5 days"
            }, 
            {
                "arm_group_label": [
                    "CJ-12420 200 mg + Clarithromycin 500mg", 
                    "CJ-12420 200mg"
                ], 
                "description": "To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.", 
                "intervention_name": "Clarithromycin 500mg", 
                "intervention_type": "Drug", 
                "other_name": "Clarithromycin 500mg for 5 days"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clarithromycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug-Drug interaction", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Inje university college of medicine Busan Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between CJ-12420 and Clarithromycin in Healthy Male Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cmax, Cmin, Tmax, AUC(tau), CL/F, T1/2", 
            "measure": "The effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin", 
            "safety_issue": "No", 
            "time_frame": "Blood sampling during 12 or 24hrs after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis, 12-lead ECG) values at Screening, Day-1 and Day 6 at each period and Follow-up.", 
            "measure": "The safety of the coadministration of multiple dose of CJ-12420 and clarithromycin in healthy subjects", 
            "safety_issue": "No", 
            "time_frame": "6 days after last visit"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}